SELLAS Life Sciences Stock Soars 255% Ahead of Key Leukemia Trial Data

SELLAS Life Sciences (SLS) has seen its stock surge by over 255% year-to-date, driven in part by investor anticipation of Phase 3 REGAL trial data for cancer drug galinpepimut-S in acute myeloid leukemia.

The trial has reached the 80-event threshold needed to trigger final analysis, which is putting the stock on traders' radars. A recent Haematologica study suggests that standard-of-care treatments for the disease may be less effective than thought, potentially benefiting SELLAS's drug.

Institutional investors have been quietly adding exposure to the company, with Quantinno Capital Management LP picking up 74,378 shares in Q1 valued at around $315,000. Despite this, analyst consensus sits at 'Hold' with a price target of $10.00, well below the current trading price of $15.46.